Company Overview - Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [6] - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [6] Alzheimer's Disease Therapeutic Development - Silo Pharma announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in the journal Alzheimer's Research & Therapy [1] - The study titled "Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease" indicates that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in Alzheimer's disease [2] - The results showed that the SPC-14 formulation improved cognitive decline by increasing memory retrieval in a fear conditioning model in mice, identifying SPC-14 as a promising drug combination for therapeutic use in Alzheimer's disease [3] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4] - SPC-14 was developed under a sponsored research agreement with Columbia University, and Silo Pharma entered into an exclusive global license agreement with the university to further develop, manufacture, and commercialize SPC-14 [4] Therapeutic Mechanism - SPC-14 is a novel intranasal therapeutic that targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer's disease [5] - In preclinical studies, SPC-14 was effective against luteinizing hormone stress, attenuating learned helplessness, perseverative behavior, and hyponeophagia, which is a measure of anxiety [5]

Core Insights - Silo Pharma, Inc. announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in a leading scientific journal, Alzheimer's Research & Therapy [1][2] - The study indicates that the combination of (R,S)-ketamine and prucalopride is a novel therapeutic strategy for treating cognitive decline in Alzheimer's disease [2] - SPC-14 has shown promising results in improving cognitive decline in preclinical models, suggesting its potential as a therapeutic option for Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including Alzheimer's disease [5] - The company has developed SPC-14 under a sponsored research agreement with Columbia University and has an exclusive global license to further develop and commercialize the product [4] - Silo's portfolio includes other innovative programs targeting conditions such as PTSD and chronic pain, indicating a broad therapeutic focus [5] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4][7] - SPC-14 targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4, addressing cognitive and neuropsychiatric symptoms associated with Alzheimer's disease [4]

Core Insights - Silo Pharma, Inc. announced positive bioanalytical and safety/toxicology results for its SPC-15 intranasal spray formulation, meeting FDA safety standards for clinical trials [1][2] - The study demonstrated that SPC-15's intranasal administration has comparable systemic exposure to oral administration while showing no identified toxicities, supporting its potential as a PTSD therapeutic [2][3] - The company is pursuing a 505(b)(2) regulatory strategy to streamline the FDA approval process by leveraging existing safety and efficacy data from approved drugs [3] Company Developments - Silo is conducting an IND-enabling GLP-compliant toxicology study and evaluating clinical CRO sites for first-in-human trials of SPC-15 [4] - The company focuses on addressing underserved conditions, including PTSD, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 and other innovative programs [5] Market Insights - The PTSD market size was valued at $1.8 billion in 2024 and is projected to reach $3.2 billion by 2034, driven by increased focus on mental health and personalized treatment solutions [5]

Company Overview - Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [6] - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [6] Product Development - Silo Pharma announced positive bioanalytical and safety/toxicology results for its lead asset SPC-15, confirming that its intranasal spray formulation meets safety standards for clinical trials [1][2] - The preclinical study demonstrated that SPC-15, administered at clinical-representative doses, showed local and systemic safety with no toxicities identified, and systemic exposure was comparable to standard oral administration [2] - The company is conducting an IND-enabling GLP-compliant toxicology and toxicokinetic animal study of SPC-15, along with a device study of the formulation-specific microchip-based nasal spray system [4] Regulatory Strategy - The study data supports Silo's planned 505(b)(2) regulatory strategy for the SPC-15 program, which allows the use of previously established safety and efficacy data to streamline the FDA drug approval process and reduce development costs [3] Market Potential - The post-traumatic stress disorder market size reached $1.8 billion in 2024 and is expected to grow to $3.2 billion by 2034, driven by increasing focus on mental health support and the need for personalized treatments and integrated care solutions [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41512 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 27-3046338 | | --- | --- | ...

Core Viewpoint - Silo Wellness Inc. has appointed Richard Craven as CEO to lead the company's strategic transition to Born Defense Inc., focusing on defense and national security investments guided by the Just War Doctrine [1][3]. Company Overview - Silo Wellness is transitioning its operations into Born Defense Inc., which will operate as a national security investment issuer committed to ethical defense finance [5]. - The restructured business model will focus on trade finance, strategic equity investments, and collateral-backed lending for pre-IPO and critical infrastructure ventures globally [5]. Leadership Background - Richard Craven brings extensive experience in financial structuring and defense-related enterprise development, having previously managed over £11.2 billion in assets and annual inflows exceeding £4 billion at a major retail investment platform [2]. - Craven has held CEO responsibilities in defense-related companies and has executed significant U.S. defense system procurement agreements [2][3]. Strategic Importance - The appointment of Craven is seen as crucial for navigating complex defense transactions and enhancing the company's global regulatory posture [3]. - The transition to Born Defense is expected to close later in 2025, pending regulatory and shareholder approval [3].

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and t ...

Core Insights - Silo Pharma, Inc. has completed dosing in a large animal study requested by the FDA for its lead asset SPC-15, with results expected in 60 days [1] - The company is confident in the safety and therapeutic delivery of SPC-15 and is on track to submit an investigational new drug (IND) application [2] - Silo plans to utilize the FDA's 505(b)(2) regulatory pathway for SPC-15, which could expedite clinical timelines and reduce development costs [3] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases [5] - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [5] - Silo collaborates with leading universities and laboratories for its research initiatives [5] Product Details - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders like PTSD and anxiety [4] - The drug has potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which may accelerate its approval process [4] - Silo Pharma has exclusive global rights for the development and commercialization of SPC-15 in collaboration with Columbia University [4]

Core Insights - Silo Pharma, Inc. is developing SPC-15, an intranasal prophylactic targeting Post-Traumatic Stress Disorder (PTSD), with plans to submit an Investigational New Drug (IND) application by the end of 2025 [1][4] - The company anticipates receiving preclinical study data for SPC-15 within 30 to 90 days, which will inform the IND application process [1][4] - SPC-15 aims to address a significant unmet need in the PTSD treatment market, as there have been no new drug approvals for PTSD in nearly 25 years, despite the condition affecting approximately 3.9% of the global population [6] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including stress-induced psychiatric disorders and chronic pain [8] - The company collaborates with Columbia University for preclinical studies and holds exclusive global rights for the development and commercialization of SPC-15 [7][8] - Silo Pharma's portfolio includes other programs targeting fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [8] Drug Development Process - The final studies for SPC-15 include a Good Laboratory Practice-compliant toxicology study and a large animal safety study requested by the FDA [2] - The company plans to utilize the FDA's 505(b)(2) regulatory pathway for SPC-15, which could expedite the approval process and reduce development costs [5] - If the IND application is approved, Silo Pharma could initiate a Phase 1 clinical trial for SPC-15 by the end of 2026 [4]

Core Insights - Silo Pharma has entered into a non-binding letter of intent to form a 50:50 joint venture with Hoth Therapeutics to develop a treatment for obesity and metabolic diseases based on technology licensed from the U.S. Department of Veterans Affairs [1][3] - The joint venture aims to leverage a novel therapeutic platform centered on glial cell line-derived neurotrophic factor (GDNF), which has shown anti-obesity effects in preclinical models [2][4] - The obesity market is valued at approximately $16 billion, with the potential for significant impact on veterans and civilians suffering from metabolic disorders [3][4] Unmet Need - Over 40% of U.S. adults are affected by obesity, which is a leading risk factor for various health issues, including diabetes and cardiovascular disease [4] - Veterans face unique challenges related to obesity, including chronic inflammation and PTSD-related metabolic disruptions, highlighting the need for effective treatments [4] Strategic Alignment - The partnership will utilize the exclusive U.S. license from the Department of Veterans Affairs, ensuring comprehensive coverage for all fields of use [7] - The joint venture structure allows for equal equity and governance participation between Silo Pharma and Hoth Therapeutics [7] - The collaboration combines the clinical infrastructure of the VA, Hoth's regulatory expertise, and Silo's translational capabilities [8]